UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION,
Petitioner,

v.

BASF PLANT SCIENCE GMBH,
Patent Owner.

U.S. Patent No. 10,533,183

Issued: January 14, 2020

DECLARATION OF NARENDRA YADAV, Ph.D., IN SUPPORT OF PETITION FOR POST-GRANT REVIEW OF U.S. PATENT NO. 10,533,183

Mail Stop: Patent Board Patent Trial and Appeal Board United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450



TABLE OF CONTENTS

I.	Intro	ntroduction1					
II.	Qualifications						
III.	Materials Considered						
IV.		Legal Standards					
	A.	Written description					
	B.	Enal	olement	4			
	C.	Enti	tlement of priority	5			
	D.	Anticipation					
	E.	Clair	m Construction	5			
	F.	Pers	on of Ordinary Skill in the Art	6			
V.	Sum	Summary of my opinions					
VI.	Tech	Technology Background1					
	A.	Fatty	Fatty acid nomenclature				
	B.	Fatty	y acid biosynthesis	13			
		1.	The aerobic biosynthetic pathway	14			
		2.	Transformation of plants with binary vectors	16			
	C.	Tria	cylglycerides and the fatty acid composition of plants	16			
		1.	Positional distribution of fatty acids in different lipid species	19			
VII.	Summary of the '183 Patent						
	A.	The	description of the '183 Patent and its priority applications	21			
		1.	The description of the '183 Patent	21			
		2.	The description of the parent and priority applications	26			
	B.	et al	description of the '183 Patent compared to the description of Ci., PCT International Application Publication No. WO 2005/0830 published September 9, 2005)93			
		1.	Binary vectors used for transformation of plant cells				
			=J :				



Declaration of Narendra Yadav, Ph.D., in Support of Petition for Post-Grant Review of U.S. Patent No. 10,533,183

	2.	The '093 publication discloses the sequence of the codon-optin	nized
		Δ5 elongase used in examples 4-13 of the '183 Patent	33
	3.	Lipids produced by transformed plants	35
VIII. Det	ailed	opinions	36
A.	Clai	im Construction	36
B.	Lac	k of entitlement to priority and unpatentability of the claims	39
	1.	Lack of entitlement to priority	39
	2.	Unpatentability of the claims	39
C.	Lac	k of written description of the claims	40
	1.	Lack of Written Description for oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant wherein said oils, lipid and/or fatty acids comprise in the sn-2 position 25% to 40% by weight of eicosapentaenoic (EPA) based on the total EPA" reci in claim 1	ted
	2.	Lack of Written Description for oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant "wherein said oils, lipid and/or fatty acids comprise in the sn-2 position 40% to 60% by weight of docosapentaenoic acid (DPA) based on the total DPA recited in claim 2	
	3.	Lack of Written Description for oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant "wherein said oils, lipid and/or fatty acids comprise in the sn-2 position 15% to 35% by weight of docosahexanoic acid (DHA) based on the total DHA recited in claim 3	,,
	4.	Lack of Written Description for "at least 20% by weight of EPA least 2% by weight of docosapentaenoic acid (DPA), and at lea 4% by weight of docosahexaenoic acid (DHA) based on the tot fatty acids in the transgenic [<i>Brassica</i>] plant in the form of triacylglycerides," recited in 1-8, and 17-23	st al
	5.	Lack of Written Description for "at least 20% long chain polyunsaturated fatty acids (LCPUFAs) based on the total fatty acids in the transgenic [<i>Brassica</i>] plant" recited in claim 5	



Declaration of Narendra Yadav, Ph.D., in Support of Petition for Post-Grant Review of U.S. Patent No. 10,533,183

	6.	Lack of Written Description for "at least about 25% by weight of EPA in the form of triacylglycerides based on the total fatty acids in the transgenic [<i>Brassica</i>] plant" recited in claim 6
	7.	Lack of Written Description for "about 30% by weight of EPA and DHA in the form of triacylglycerides based on the total fatty acids in the transgenic [<i>Brassica</i>] plant" recited in claim 7
	8.	Lack of Written Description for oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant comprising "at least 54% by weight of polyunsaturated ω3-fatty acids" recited in claim 856
D.	Lac	k of Enablement of the Claims61
	1.	Lack of Enablement of oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant "wherein said oils, lipids and/or fatty acids comprise in the sn-2 position 25% to 40% by weight of eicosapentaenoic (EPA) based on the total EPA" recited in claim 1
	2.	Lack of Enablement of oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant "wherein said oils, lipids and/or fatty acids comprise in the sn-2 position 25% to 40% by weight of eicosapentaenoic (EPA) based on the total EPA" recited in claim 1
	3.	Lack of Enablement of oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant "wherein said oils, lipids and/or fatty acids comprise in the sn-2 position 25% to 40% by weight of eicosapentaenoic (EPA) based on the total EPA" recited in claim 1
	4.	Lack of Enablement of oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant comprising "at least 20% by weight of EPA", "at least 2% by weight of DPA", or "at least 4% by weight of DHA", "based on the total fatty acids in the transgenic [<i>Brassica</i>] plant in the form of triacylglycerides" recited in claim 4
	5.	Lack of Enablement of oils, lipids and/or fatty acids produced by a transgenic <i>Brassica</i> plant comprising "at least 20% long chain



Declaration of Narendra Yadav, Ph.D., in Support of Petition for Post-Grant Review of U.S. Patent No. 10,533,183

			fatty acids in the transgenic [Brassica] plant", recited in claim 7	71	
		8.	Lack of Enablement of oils, lipids and/or fatty acids produced by transgenic <i>Brassica</i> plant comprising "at least 54% by weight of polyunsaturated ω3-fatty acids", recited in claim 8		
	E.	Δnt	icipation of the claims		
	E.			/4	
		1.	Claims 1-3 and 5-9 are Anticipated by Wu et al. (2005) Nat. Biotech. 1013-1017	74	
		2.	Claims 1-9 are Anticipated by, or obvious over, WO 2005/083093 (BASF Plant Science GmbH)		
		3.	Claims 1-9 are obvious over Wu et al. in view of the '093 publication	82	
IX.	Sun	plem	entation		
	-	•			
Χ.	Conclusion				



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

